Innovation Showcases
In modern cell therapy manufacturing, the transition from serum-based culture systems to chemically defined, animal-origin-free (AOF) media has become essential to ensure enhanced safety, reproducibility, and regulatory compliance. Conventional use of fetal bovine serum (FBS) presents significant challenges, including the risk of xenoantigen exposure, heightened immunogenicity, and ethical and environmental concerns. Specifically, FBS introduces foreign proteins such as Neu5Gc and extracellular vesicle (EV) contaminants, which may lead to immune rejection and compromise therapeutic efficacy. Technological advancements now enable the use of chemically defined media that achieve equivalent or superior cell proliferation without reliance on animal-derived components, thereby minimizing variability and contamination risks.
Xcell Therapeutics' CellCor CD AOF media exemplifies these advances, demonstrating superior consistency, reduced immunogenicity, and suitability for clinical and industrial applications. It supports not only traditional two-dimensional cultures but also emerging technologies such as 3D cell culture, organoid development, extracellular vesicle production, and bioprinting. Transitioning to AOF, chemically defined systems is no longer an option but a necessity to advance safe, ethical, and sustainable regenerative medicine. Through collaborative innovation, we aim to lead the future of cell and gene therapies by providing reliable, high-quality media solutions tailored to evolving scientific and clinical needs.